Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) today reported financial results for the three and nine months ended September 30, 2014, outlined upcoming milestones in its development programs for chronic hepatitis C viral infection (HCV), and introduced a novel platform for advancing oral complement factor D inhibitors. For the third quarter of 2014, Achillion reported a net loss of $15.7 million or $0.16 per share, compared with a net loss of $13.9 million or $0.14 per share for the third quarter of 2013. Cash, cash equivalents, marketable securities, and interest receivable as of September 30, 2014 were $127.1 million.Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) belongs to Healthcare sector. Its weekly performance is 2.97%. On last trading day company shares ended up $12.12. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average (SMA50) is 7.60%.Microsoft Corporation (NASDAQ:MSFT) has detailed the Windows Phone 8.1 Update 1 plus Lumia Denim upcoming firmware release. It is going to roll out by the end of this year and will be available to all Windows Phone 8-running Lumia phones. Microsoft Corporation (NASDAQ:MSFT) shares moved up 1.04% in last trading session and ended the day at $47.44. MSFT Gross Margin is 67.10% and its return on assets is 13.10%. Microsoft Corporation (NASDAQ:MSFT) quarterly performance is 10.82%.Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the target enrollment of 300 patients has been achieved in the company's multicenter, randomized, open-label Phase 3 study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the current standard of care, conventional cytarabine and daunorubicin therapy (7+3) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML). On 03 November, Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) shares moved up 1.91% and was closed at $2.13. CPXX EPS growth in last 5 year was 0.00%. Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) year to date (YTD) performance is -34.46%.The WWE Network, which was set for an 8pm launch on November 3rd in the UK, was indefinitely postponed just 20 minutes prior to its scheduled rolling out. World Wrestling Entertainment Inc. (NYSE:WWE) simply posted: “The launch of WWE Network in the UK has been delayed until further notice” on its Twitter account at 7:39pm – offering no explanation for the postponement. World Wrestling Entertainment Inc. (NYSE:WWE) ended the last trading day at $13.04. Company weekly volatility is calculated as 5.08% and price to cash ratio as 12.46. World Wrestling Entertainment Inc. (NYSE:WWE) showed a weekly performance of -3.41%.Miami-based Platform Specialty Products Corp. (NYSE:PAH) plans to acquire Arysta LifeScience Ltd. for $3.5 billion, pending regulatory approval. Platform, owned by international equity firm Permira, had previously acquired Chemtura AgroSolutions and Agriphar, a European agricultural chemical company. Platform Specialty Products Corporation (NYSE:PAH) shares decreased -0.92% in last trading session and ended the day at $25.76. Platform Specialty Products Corporation (NYSE:PAH) quarterly performance is 1.86%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
